3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Brain Neoplasms
19
Neoplasm Metastasis
13
Lung Neoplasms
13
Pancreatic Neoplasms
11
Melanoma
10
Carcinoma, Renal Cell
9
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Prostatic Neoplasms
6
Neoplasms
6
Glioblastoma
6
Breast Neoplasms
6
Liver Neoplasms
5
Head and Neck Neoplasms
4
Glioma
3
Colorectal Neoplasms
3
Uveal Melanoma
2
Sarcoma
2
Mesothelioma
2
Gliosarcoma
2
Gastrointestinal Neoplasms
2
Cholangiocarcinoma
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor
1
Spinal Cord Compression
1
Secondary Malignant Neoplasm of Liver
1
Sarcoma, Ewing
1
Interventions
Capecitabine
35
Oxaliplatin
32
Fluorouracil
29
Leucovorin
26
Irinotecan
22
Bevacizumab
19
Cetuximab
17
Radiotherapy
16
Radiation
11
Surgical Procedures, Operative
6
Radiotherapy, Intensity-Modulated
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
Celecoxib
5
Neoadjuvant Therapy
4
Immunohistochemistry
4
Biopsy
4
Amplified Fragment Length Polymorphism Analysis
4
cediranib
3
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Folfox protocol
3
Drug Therapy
3
Cisplatin
3
sargramostim
2
regorafenib
2
pembrolizumab
2
fludarabine phosphate
2
aldesleukin
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Rectal Neoplasms
×
Radiosurgery
×
Clear all
NCT01729923
2018-01-16
ADAPT
University of Washington
Phase 2
Terminated
27 enrolled
10 charts